[{"NetIncomeLoss_1_Q2_USD":-107245000.0,"WeightedAverageNumberOfShareOutstandingBasicAndDiluted_1_Q2_shares":58582569.0,"CommitmentsAndContingencies_0_Q2_USD":null,"AccruedLiabilitiesCurrent_0_Q2_USD":61623000.0,"TreasuryStockCommonShares_0_Q2_shares":3033.0,"SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares_1_Q2_shares":113941.0,"AccumulatedOtherComprehensiveIncomeLossNetOfTax_0_Q2_USD":-285000.0,"RestrictedCashAndCashEquivalentsNoncurrent_0_Q2_USD":1269000.0,"NetCashProvidedByUsedInInvestingActivities_2_Q2_USD":-947204000.0,"Depreciation_1_Q2_USD":900000.0,"Depreciation_2_Q2_USD":3475000.0,"InterestIncomeExpenseNonoperatingNet_2_Q2_USD":1440000.0,"InterestIncomeExpenseNonoperatingNet_1_Q2_USD":732000.0,"AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_0_Q2_USD":446000.0,"AssetsCurrent_0_Q2_USD":1988599000.0,"PaymentsToAcquireAvailableForSaleSecuritiesDebt_2_Q2_USD":1308143000.0,"SellingGeneralAndAdministrativeExpense_2_Q2_USD":83193000.0,"SellingGeneralAndAdministrativeExpense_1_Q2_USD":43346000.0,"ProceedsFromCollaborators_2_Q2_USD":1000000000.0,"AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_2_Q2_shares":7410721.0,"AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_1_Q2_shares":7410721.0,"StockIssuedDuringPeriodValueStockOptionsExercised_1_Q2_USD":6861000.0,"OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax_1_Q2_USD":-49000.0,"ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities_2_Q2_USD":360939000.0,"CommonStockSharesIssued_0_Q2_shares":58773397.0,"IncreaseDecreaseInAccountsReceivableRelatedParties_2_Q2_USD":48438000.0,"WeightedAverageNumberOfShareOutstandingBasicAndDiluted_2_Q2_shares":58478970.0,"MarketableSecuritiesCurrent_0_Q2_USD":1397157000.0,"PreferredStockSharesOutstanding_0_Q2_shares":0.0,"TreasuryStockCommonValue_0_Q2_USD":400000.0,"ResearchAndDevelopmentExpense_2_Q2_USD":124226000.0,"ResearchAndDevelopmentExpense_1_Q2_USD":66170000.0,"ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_2_Q2_shares":0.0,"WeightedAverageNumberOfDilutedSharesOutstanding_2_Q2_shares":58478970.0,"WeightedAverageNumberOfDilutedSharesOutstanding_1_Q2_shares":58582569.0,"AssetsFairValueDisclosure_0_Q2_USD":1911315000.0,"OtherNonoperatingIncomeExpense_2_Q2_USD":79000.0,"OtherNonoperatingIncomeExpense_1_Q2_USD":44000.0,"InvestmentIncomeNetAmortizationOfDiscountAndPremium_2_Q2_USD":-4688000.0,"CommonStockValue_0_Q2_USD":6000.0,"Revenues_2_Q2_USD":3226000.0,"Revenues_1_Q2_USD":1643000.0,"Assets_0_Q2_USD":2015475000.0,"NetCashProvidedByUsedInFinancingActivities_2_Q2_USD":11688000.0,"ComprehensiveIncomeNetOfTax_2_Q2_USD":-203709000.0,"ComprehensiveIncomeNetOfTax_1_Q2_USD":-107294000.0,"IncreaseDecreaseInAccountsPayable_2_Q2_USD":-774000.0,"OtherAssetsNoncurrent_0_Q2_USD":3599000.0,"CashAndCashEquivalentsAtCarryingValue_0_Q2_USD":514158000.0,"OperatingLeaseLiabilityNoncurrent_0_Q2_USD":13964000.0,"AdditionalPaidInCapitalCommonStock_0_Q2_USD":3170694000.0,"Liabilities_0_Q2_USD":85963000.0,"ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_0_Q2_shares":1014488.0,"ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions_2_Q2_USD":12484000.0,"OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_2_Q2_USD":-700000.0,"OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_1_Q2_USD":-49000.0,"RestrictedCash_0_Q2_USD":700000.0,"OtherComprehensiveIncomeLossNetOfTax_2_Q2_USD":-700000.0,"OtherComprehensiveIncomeLossNetOfTax_1_Q2_USD":-49000.0,"IncrementalCommonSharesAttributableToConversionOfPreferredStock_2_Q2_shares":0.0,"AccountsReceivableRelatedPartiesCurrent_0_Q2_USD":48438000.0,"ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_0_Q2_shares":8979250.0,"RetainedEarningsAccumulatedDeficit_0_Q2_USD":-1240503000.0,"CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_2_Q2_USD":-1147371000.0,"AssetImpairmentCharges_2_Q2_USD":0.0,"CommonStockSharesOutstanding_0_Q2_shares":58770364.0,"InvestmentsFairValueDisclosure_0_Q2_USD":1397157000.0,"AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_0_Q2_USD":4675000.0,"AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_0_Q2_USD":161000.0,"PaymentsRelatedToTaxWithholdingForShareBasedCompensation_2_Q2_USD":796000.0,"AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_1_Q2_USD":27465000.0,"NetCashProvidedByUsedInOperatingActivities_2_Q2_USD":-211855000.0,"AvailableForSaleDebtSecuritiesAmortizedCostBasis_0_Q2_USD":1397442000.0,"WeightedAverageNumberOfSharesOutstandingBasic_2_Q2_shares":58478970.0,"LiabilitiesCurrent_0_Q2_USD":71898000.0,"AccountsPayableCurrent_0_Q2_USD":2917000.0,"PrepaidExpenseAndOtherAssetsCurrent_0_Q2_USD":28846000.0,"CashAndCashEquivalentsFairValueDisclosure_0_Q2_USD":514158000.0,"OtherAccruedLiabilitiesCurrent_0_Q2_USD":733000.0,"AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipmentPeriodIncreaseDecrease_2_Q2_USD":-1800000.0,"ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue_1_Q2_USD":8800000.0,"CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_0_Q2_USD":515427000.0,"PreferredStockSharesIssued_0_Q2_shares":0.0,"PropertyPlantAndEquipmentGrossPeriodIncreaseDecrease_2_Q2_USD":-1800000.0,"PropertyPlantAndEquipmentNet_0_Q2_USD":3280000.0,"NetIncomeLoss_2_Q2_USD":-203009000.0,"WeightedAverageNumberOfSharesOutstandingBasic_1_Q2_shares":58582569.0,"IncreaseDecreaseInOtherNoncurrentAssets_2_Q2_USD":258000.0,"StockholdersEquity_0_Q2_USD":1929512000.0,"ProfitLoss_2_Q2_USD":-203009000.0,"IncrementalCommonSharesAttributableToConversionOfPreferredStock_1_Q2_shares":0.0,"ShareBasedCompensation_2_Q2_USD":49639000.0,"OperatingLeaseRightOfUseAsset_0_Q2_USD":18728000.0,"PreferredStockParOrStatedValuePerShare_0_Q2_USD":0.0001,"CommonStockParOrStatedValuePerShare_0_Q2_USD":0.0001,"ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_2_Q2_USD":54.51,"IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_2_Q2_USD":6025000.0,"CommonStockSharesAuthorized_0_Q2_shares":120000000.0,"OperatingIncomeLoss_2_Q2_USD":-204528000.0,"OperatingIncomeLoss_1_Q2_USD":-108021000.0,"ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_0_Q2_shares":5402463.0,"AvailableForSaleSecuritiesDebtSecuritiesCurrent_0_Q2_USD":1397157000.0,"OtherLiabilitiesNoncurrent_0_Q2_USD":101000.0,"PreferredStockValue_0_Q2_USD":null,"EmployeeRelatedLiabilitiesCurrent_0_Q2_USD":8283000.0,"PreferredStockSharesAuthorized_0_Q2_shares":5000000.0,"AllocatedShareBasedCompensationExpense_2_Q2_USD":49639000.0,"AllocatedShareBasedCompensationExpense_1_Q2_USD":27663000.0,"StockIssuedDuringPeriodValueRestrictedStockAwardGross_1_Q2_USD":-796000.0,"PropertyPlantAndEquipmentGross_0_Q2_USD":7955000.0,"OperatingLeaseLiabilityCurrent_0_Q2_USD":7358000.0,"OperatingExpenses_2_Q2_USD":207754000.0,"OperatingExpenses_1_Q2_USD":109664000.0,"IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities_2_Q2_USD":5966000.0,"EarningsPerShareBasicAndDiluted_2_Q2_USD":-3.47,"EarningsPerShareBasicAndDiluted_1_Q2_USD":-1.83,"LiabilitiesAndStockholdersEquity_0_Q2_USD":2015475000.0,"AccruedProfessionalFeesCurrent_0_Q2_USD":9438000.0,"Ticker":"SAGE","CIK":"1597553","name":"SAGE THERAPEUTICS, INC.","OfficialName":"Sage Therapeutics Inc. Common Stock","form":"10-Q","period":"20210630","fy":"2021.0","fp":"Q2","qtrs":"1","uom":"USD","footnote":"nan","Market Cap":"2034401653.0","Country":"United States","Sector":"Health Care","Industry":"Biotechnology: Pharmaceutical Preparations","Market":"NASDAQ","SP500":"nan","filed":"20210803"}]